Clinical Trial

CMV-associated Immunomodulation in Renal Transplant Patients

Study acronym: IMMCMV
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-09; most recent amendment 2025-09-05.
Trial Details
NCT Number NCT06976008
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Collaborators: URC-CIC Paris Descartes Necker Cochin
Conditions Kidney Transplantation
Enrollment 60 participants
Start Date 2025-10-01
Primary Completion 2029-10-01 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-12